186 related articles for article (PubMed ID: 27780599)
21. Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients.
Klotz LV; Casjens S; Johnen G; Taeger D; Brik A; Eichhorn F; Förster L; Kaiser N; Muley T; Stolp C; Schneider M; Gleichenhagen J; Brüning T; Winter H; Eichhorn M; Weber DG
Lung Cancer; 2024 Jun; 192():107802. PubMed ID: 38692217
[TBL] [Abstract][Full Text] [Related]
22. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
Rrapaj E; Trisolini E; Bertero L; Salvo M; Indellicato R; Andorno S; Garcia-Manteiga JM; Rena O; Boldorini RL
Histopathology; 2018 May; 72(6):1039-1050. PubMed ID: 29356044
[TBL] [Abstract][Full Text] [Related]
23. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
24. Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall.
Askan G; Basturk O
Turk Patoloji Derg; 2021; 37(2):115-120. PubMed ID: 33432559
[TBL] [Abstract][Full Text] [Related]
25. Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.
Righi L; Cavallo MC; Gatti G; Monica V; Rapa I; Busso S; Albera C; Volante M; Scagliotti GV; Papotti M
Am J Clin Pathol; 2014 Jun; 141(6):816-27. PubMed ID: 24838326
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.
Vivero M; Bueno R; Chirieac LR
Mod Pathol; 2018 Jan; 31(1):122-131. PubMed ID: 28884745
[TBL] [Abstract][Full Text] [Related]
27. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
[TBL] [Abstract][Full Text] [Related]
28. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
29. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
30. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
[TBL] [Abstract][Full Text] [Related]
31. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
33. CD74: a new prognostic factor for patients with malignant pleural mesothelioma.
Otterstrom C; Soltermann A; Opitz I; Felley-Bosco E; Weder W; Stahel RA; Triponez F; Robert JH; Serre-Beinier V
Br J Cancer; 2014 Apr; 110(8):2040-6. PubMed ID: 24594996
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
[TBL] [Abstract][Full Text] [Related]
35. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
36. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
[TBL] [Abstract][Full Text] [Related]
37. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
38. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
39. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
Kadota K; Suzuki K; Colovos C; Sima CS; Rusch VW; Travis WD; Adusumilli PS
Mod Pathol; 2012 Feb; 25(2):260-71. PubMed ID: 21983936
[TBL] [Abstract][Full Text] [Related]
40. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]